The Importance of the Adequate Empiric Antimicrobial Therapy in Nosocomial Infections Caused by *Acinetobacter baumannii*

Yu.L.  Gorbich; A. Karpov Igor

The Importance of the Adequate Empiric Antimicrobial Therapy in Nosocomial Infections Caused by Acinetobacter baumannii

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(1):67-73

Gorbich Yu.L., Karpov I.A.

Acinetobacter baumannii nosocomial infections empiric antimicrobial therapy mortality

Section

Personal Experience

Type

Journal article

Publication

Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(1):67-73

Abstract Literature PDF Statistics

Objective.

To evaluate the influence of adequate empiric antimicrobial therapy for the outcome and the length of hospitalization in patients with nosocomial infections, caused by Acinetobacter baumannii.

Materials and Methods.

The subject of the research was 42 patients with nosocomial infections, caused by A. baumannii (middle age 53.3±5 year; 61.9% were males). The evaluation of the interrelation between patient’s outcome and adequacy of the empiric antimicrobial therapy was performed using odds ratio method and χ2-criterion to prove the results. The statistical significance of the difference in the length of hospitalization between both patients’ groups (adequate/inadequate empiric therapy) was evaluated by Wilcoxon signed-rank test.

Results.

The adequate initial antimicrobial therapy has significantly increased the favorable outcomes odds (OR 11.1; χ2=7.6; p<0.05). The mortality among studied patients was 50%. All died patients received inadequate empiric antibiotic therapy. The difference in the length of hospital stay between studied groups wasn’t statistically significant.

Conclusions.

The delay in the adequate antimicrobial therapy at the initial stage of treatment has produced considerable negative effect for the outcome in patients with A. baumannii-associated infections. Because of multidrug-resistance and differences in the resistance phenotypes between hospitals, the empiric antimicrobial therapy should be based on the local susceptibility data.

Gorbich Yu.L.

Igor A. Karpov

1. Иванов Д.В., Крапивина И.В., Галева Е.В. Нозокомиальные инфекции: эпидемиология, патогенез, этиология, антибактериальная терапия и профилактика. Антибиотики и химиотерапия 2005; 50(12):19-28.
2. Козлов Р.С. Выбор антибиотиков при нозокомиальных инфекциях в отделениях интенсивной терапии на основе данных многоцентрового исследования резистентности грамотрицательных возбудителей [автореф. дис. … канд. мед. наук]. Смоленская государственная медицинская академия. – Смоленск, 1998. – 23 с.
3. Розанова С.М., Руднов В.А., Перевалова Е.Ю. и др. Сравнительный анализ этиологии и антибиотикорезистентности основных возбудителей нозокомиальных инфекций в ОРИТ различного профиля города Екатеринбурга. Клин микробиол антимикроб химиотер 2005; 7(4):410-8.
4. Marchaim D., Zaidenstein R., Lazarovitch T., Karpuch Y., Ziv T, Weinberger M. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotic resistance and patient age. Eur J Clin Microbiol Infect Dis 2008; 27(11):1045-51.
5. Velasco E., Soares M., Byington R., et al. Prospective evaluation of the epidemiology, microbiology and outcome of bloodstream infections in adult surgical cancer patients. Eur J Clin Microbiol Infect Dis 2004; 23(8):596-602.
6. Яковлев С.В. Нозокомиальные инфекции, вызванные полирезистентными грамотрицательными микроорганизмами: как с ними бороться? Consilium medicum 2008; 10(1):44-9.
7. Wolf H.-H., Leithauser M., Maschmeyer G., et al. Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2008; 87(11):863-76.
8. Козлов Р.С. Нозокомиальные инфекции: эпидемиология, патогенез, профилактика, контроль // Клин микробиол антимикроб химиотер 2000; 2(1):16-30.
9. Коршунова Г.С. Эпидемиологическая ситуация по внутрибольничным инфекциям в Российской Федерации в 1997-2001 гг. (доклад на 8-м съезде эпидемиологов, микробиологов и паразитологов). Эпидемиол и инфекц болезни 2002; (6):22-4.
10. Решедько Г.К., Рябкова Е.Л., Кречикова О.И. и др. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клин микробиол антимикроб химиотер 2008; 10(2):163-79.
11. Fournier P.E., Vallenet D., Barbe V., et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLOS Genet 2006; 2(1):62-72.
12. Marioni G., Marchese-Ragona R., Boldrin C., et al. Deep neck abscess due to Acinetobacter baumannii infection. Am J Otolaryngol 2010; 31(4):304-7.
13. Brahmi N., Blel Y., Kouraichi N., et al. Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit. J Infect Chemother 2006; 12(4):190-4.
14. Xu X.F., Ma X.L., Chen Z., Shi L.P., Du L.Z. Clinical characteristics of nosocomial infections in neonatal intensive care unit in eastern China. J Perinat Med 2010; 38(4):431-7.
15. Asghar A.H., Faidah H.S. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Saudi Med J 2009; 30(8):1017-23.
16. Lagamayo E.N. Antimicrobial resistance in major pathogens of hospital acquired pneumonia in Asian countries. Am J Infect Control 2008; 36(4 Suppl.2):101-8.
17. Raka L., Kalenc S., Bosnjak Z. et al. Molecular epidemiology of Acinetobacter baumannii in central intensive care unit in Kosova Teaching Hospital. Braz J Infect Dis 2009;13(6): 408-13.
18. Рябкова Е.Л., Иванчик Н.В., Сухорукова М.В. Резистентность нозокомиальных штаммов Escherichia coli в стационарах России. Клин микробиол антимикроб химиотер 2009; 11(2):161-9.
19. Воробьева О.Н., Камалеева М.Ф., Жилина Н.М., Чеченин Г.И., Челпанова Л.И. Этиологическая структура нозокомиальных инфекций у больных в отделении реанимации и интенсивной терапии. Российский медико-биологический вестник имени академика И.П.Павлова 2009; 1:33-8.
20. Фаращук А.Н. Оптимизация антибиотикотерапии нозокомиальных инфекций, вызванных Acinetobacter baumannii, в отделениях реанимации и интенсивной терапии России: автореф. дис. … канд. мед. наук; Смоленская государственная медицинская академия. – Смоленск, 2008. – 22 с.
21. Решедько Г.К., Рябкова Е.Л., Козлов Р.С. Современные аспекты эпидемиологии диагностики и лечения нозокомиальной пневмонии. Клин микробиол антимикроб химиотер 2008; 10(2):143-53.
22. Wisplinghoff H., Hippler C., Bartual S., et al. Molecular epidemiology of clinical Acinetobacter baumannii isolates from Europe and The U.S. using a new MLST scheme. 45th ICAAC. Abstract C2-1428, P.126.
23. Ортенберг Э.А., Ушакова М.А., Вешкурцева И.М., Рожаев М.В. Ингибиторозащищенные бета-лактамы: место в современных схемах антибактериальной терапии. Клин микробиол антимикроб химиотер 2005; 7(4):393-402.
24. Giamarellou H., Antoniadou A., Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2006; 32(2):106-19.
25. Karageorgopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8(12):751-62.
26. Руднов В.А., Зубарев А.С. Инфекции в отделениях реанимации и интенсивной терапии, вызванные P.aeruginosa и Acinetobacter spp. Consilium medicum 2008; 10(1):37-44.
27. Katsaragakis S., Markogiannakis H., Toutouzas K.G., et al. Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance. World J Surg 2008; 32(6):1194-202.
28. Enoch D.A., Summers C., Brown N.M., et al. Investigation and management of an outbreak of multidrug-carbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J of Hosp Infect 2008; 70(2):109-18.
29. Falagas M.E., Karveli E.A. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications. Clin Microbiol Infect 2007; 13(2):117–9.
30. van Looveren M., Goossens H. and the ARPAC Steering Group Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10(8):684–704.
31. Горбич Ю.Л., Карпов И.А., Кречикова О.И., Левшина Н.Н. Ацинетобактер-ассоциированные инфекции в Республике Беларусь. Мед. новости 2010; (3):75-9.
32. Dauner D.G., May J.R., Steele J.C.H. Assessing antibiotic therapy for Acinetobacter baumannii infections in an academic medical center. Eur J Clin Microbiol Infect Dis 2008; 27(11):1021-4.
33. Chen S.-Y., Wu G.H-M., Chang S.-C., et al. Bacteremia in previously hospitalized patients: prolonged effect from previous hospitalization and risk factors for antimicrobial-resistant bacterial infections. Annals of Emergency Medicine 2008; 51(5):639-46.
34. Erbay A., Idil A., Gozel M.G., Mumcuoglu I., Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34(6):575-9.
35. Fagon J.-Y., Rello J. Targeted antibiotic management of ventilator-associated pneumonia. Clin Microbiol Infect 2006; 12(Suppl. 9):17-22.
36. Garnacho-Montero J., Ortiz-Leyba C., FernandezHinojosa E. et al. Acinetobacter baumannii ventilatorassociated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31(5):649-55.
37. Kuti E.L., Patel A.A., Coleman C.I. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: A meta-analysis. Crit Care 2008; 23(1):91-100.
38. Leroy O., d’Escrivan T., Devos P., Dubreuil L., Kipnis E., Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005; 33(3):129-35.
39. Masterton R.G. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009; 33(2):105-10.
40. Richards G.A. The therapeutic challenge of Gramnegative sepsis: prolonging the lifespan of a scarce resource. Clin Microbiol Infect 2005; 11(Suppl. 6):18-22.
41. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27(5):887-92.
42. Jang T.N., Lee S.H., Huang C.H., Lee C.L., Chen W.Y. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 2009; 73(2):143-50.
43. Rello J., Diaz E. Acinetobacter baumannii: a threat for the ICU? Intensive Care Med 2003; 29(3):350-1.
44. Routsi C., Pratikaki M., Platsouka E., et al. Carbapenemresistant versus carbapenem-susceptible Acinetobacter baumannii bacteriemia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38(3):173-80.
45. Siempos I.I., Vardakas K.Z., Kyriakopoulos C.E., Ntaidou T.K., Falagas M.E. Predictors of mortality in adult patients with ventilator-associated pneumonia: a metaanalysis. Shock 2010; 33(6):590-601.
46. Abbo A., Carmelli Y., Navon-Venezia S., et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26(11):793-800.
47. Kuo L.-C., Lai C.-C., Liao C.-H. et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13(2):196-8.
48. del Mar Tomas M., Cartelle M., Pertega S. et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonization and infection. Clin Microbiol Infect 2005; 11(7):540-6.
49. Mastoraki A., Douka E., Kriaras I., et al. Preventing strategy of multidrug-resistant Acinetobacter baumannii susceptible only to colistin in cardiac surgical intensive care units. Eur J Cardiothorac Surg 2008; 33(6):1086-90.
50. Katsaragakis S., Markogiannakis H., Samara E., et al. Predictors of mortality of Acinetobacter baumannii infections: A 2-year prospective study in a Greek surgical intensive care unit. Am J Infect Control 2010; 38(8):631-5.

Views

0 Abstract

0 PDF

0 Crossref citations